Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic : An EAACI statement

Autor: Paula Kauppi, Andrea Matucci, Sevim Bavbek, Adam Chaker, Ioana Agache, Davide Firinu, Marek Jutel, Oscar Palomares, Eva Untersmayr, Barbara Rogala, Thomas Eiwegger, Mübeccel Akdis, Onur Boyman, Alexia Chatzipetrou, Susan Chan, Apostolos Bossios, Wojciech Feleszko, Antonios G.A. Kolios, Cezmi A. Akdis, Jean Bousquet, Ludger Klimek, Akash Kothari, Marek L. Kowalski, Oliver Pfaar, Alessandra Vultaggio
Přispěvatelé: HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Helsinki University Hospital Area, University of Zurich, Eiwegger, Thomas, Careggi University Hospital [Florence, Italie], Transylvania University of Brasov, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Ankara University School of Medicine [Turkey], Karolinska University Hospital [Stockholm], Karolinska Institutet [Stockholm], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University hospital of Zurich [Zurich], University Hospital of the Technical University Munich, Guy's and St Thomas NHS Foundation Trust [London], University General Hospital ' Attikon ' [Athens, Greece], Medical University of Warsaw - Poland, University of Cagliari, Wrocław Medical University, ALL-MED Medical Research Institute, Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Centre for Rhinology and Allergy, CHU Montpellier, Beth Israel Deaconess Medical Center [Boston] (BIDMC), Harvard Medical School [Boston] (HMS), The Hospital for sick children [Toronto] (SickKids), Medical University of Łódź (MUL), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Philipps Universität Marburg = Philipps University of Marburg, Medical University of Silesia (SUM), Medizinische Universität Wien = Medical University of Vienna, University of Toronto, Salvy-Córdoba, Nathalie
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Eaaci Position Paper
Disease
GUIDELINES
IMMUNOLOGY
0302 clinical medicine
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
10183 Swiss Institute of Allergy and Asthma Research
Pandemic
MESH: COVID-19
Immunology and Allergy
Nasal polyps
[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases
Academies and Institutes
Atopic dermatitis
3. Good health
Europe
INFECTIONS
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
2723 Immunology and Allergy
medicine.symptom
[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology
MESH: Pandemics
medicine.medical_specialty
MESH: Biological Products
MESH: Hypersensitivity
MESH: Academies and Institutes
610 Medicine & health
Inflammation
03 medical and health sciences
OMALIZUMAB
medicine
Hypersensitivity
Humans
IGE
Intensive care medicine
Pandemics
Asthma
2403 Immunology
Biological Products
MESH: Humans
business.industry
Outbreak
COVID-19
medicine.disease
030104 developmental biology
030228 respiratory system
3121 General medicine
internal medicine and other clinical medicine
10033 Clinic for Immunology
ASTHMA
MESH: Europe
Cytokine storm
business
RESPONSES
Zdroj: Allergy
Allergy, 2020, 75 (11), pp.2764-2774. ⟨10.1111/all.14407⟩
ISSN: 0105-4538
1398-9995
DOI: 10.1111/all.14407⟩
Popis: International audience; The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a "cytokine storm" and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded.
Databáze: OpenAIRE
Externí odkaz: